Bayer Posts In-Line 4Q, Buoyed by Strong Drug Sales; Monsanto Deal Expected to Close in 2Q
Bayer reported fourth-quarter results that were largely in line our expectations, and we don’t plan any major changes to our fair value estimate; we continue to view the stock as undervalued, supported by our above-consensus expectations for cardiovascular drug Xarelto and several pipeline drugs. Additionally, the company expects to complete the Monsanto acquisition in the second quarter, which is in line with our expectation that the deal will close midyear. We maintain a 75% probability that t...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.